MB Financial Advisors AG announcement: Co-Diagnostics, receives first tranche of financing from New York investment bank
ZURICH, SWITZERLAND, January 10, 2017 /EINPresswire.com/ -- MB Financial Advisors AG of Zurich, Switzerland, announced today that Co-Diagnostics Inc, an investment capital client of MB Financial, received its first tranche of financing from its New York City-based investment banking partner. This funding is structured as bridge financing to an anticipated initial public offering, and Co-Diagnostics intends to file an S-1 registration statement with the SEC as soon as possible.
With the arrival of this funding and given planned future activities in the public domain, Co-Diagnostics will enter into a “quiet period” regarding disclosure of information concerning their progress.
About MB Financial Advisors
MB Financial Advisors AG is a professional team of independent financial advisors headquartered in Zurich, Switzerland. MB Financial provides customised advisory and consulting services to Private Equity companies and individuals throughout Switzerland and beyond.
www.mbadvisors.ch
About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, is a Utah corporation based in Sandy, Utah that develops, manufactures and markets fully integrated DNA test systems. The company’s intellectual property is based on mathematical principles that create algorithms in a unique DNA-based diagnostics system that is superior in cost and speed of development to all other such systems, both in the US and abroad.
www.codiagnostics.com
Disclosures and Forward-Looking Statements
MB Financial Advisors did not participate in the financing discussed in this release, and will not participate in nor underwrite any follow-on offering, public or otherwise. This press release includes forward-looking statements regarding Co-Diagnostics’ (the Company’s) continuing business efforts related to its products, including but not limited to, statements regarding future stock registration activities and other similar statements. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: (i) the Company’s limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; and (iii) the Company’s ability to obtain capital when needed. These forward-looking statements speak only as of the date hereof and all parties specifically disclaim any obligation to update these forward-looking statements, except as required by law.
With the arrival of this funding and given planned future activities in the public domain, Co-Diagnostics will enter into a “quiet period” regarding disclosure of information concerning their progress.
About MB Financial Advisors
MB Financial Advisors AG is a professional team of independent financial advisors headquartered in Zurich, Switzerland. MB Financial provides customised advisory and consulting services to Private Equity companies and individuals throughout Switzerland and beyond.
www.mbadvisors.ch
About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, is a Utah corporation based in Sandy, Utah that develops, manufactures and markets fully integrated DNA test systems. The company’s intellectual property is based on mathematical principles that create algorithms in a unique DNA-based diagnostics system that is superior in cost and speed of development to all other such systems, both in the US and abroad.
www.codiagnostics.com
Disclosures and Forward-Looking Statements
MB Financial Advisors did not participate in the financing discussed in this release, and will not participate in nor underwrite any follow-on offering, public or otherwise. This press release includes forward-looking statements regarding Co-Diagnostics’ (the Company’s) continuing business efforts related to its products, including but not limited to, statements regarding future stock registration activities and other similar statements. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: (i) the Company’s limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; and (iii) the Company’s ability to obtain capital when needed. These forward-looking statements speak only as of the date hereof and all parties specifically disclaim any obligation to update these forward-looking statements, except as required by law.
Paul Barnett
MB Financial Advisors AG
+41 435 086 312
email us here